Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis.

[1]  M. Caetano,et al.  T helper 17 cells play a critical pathogenic role in lung cancer , 2014, Proceedings of the National Academy of Sciences.

[2]  Y. Iwakura,et al.  Alterations in the microbiota drive interleukin-17C production from intestinal epithelial cells to promote tumorigenesis. , 2014, Immunity.

[3]  Zhaoshi Jiang,et al.  An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy , 2013, Nature Medicine.

[4]  O. Sieber,et al.  Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. , 2013, Cancer cell.

[5]  Kathleen R. Cho,et al.  Sox9 induction, ectopic Paneth cells, and mitotic spindle axis defects in mouse colon adenomatous epithelium arising from conditional biallelic Apc inactivation. , 2013, The American journal of pathology.

[6]  D. Patel,et al.  Effect of IL-17A blockade with secukinumab in autoimmune diseases , 2012, Annals of the rheumatic diseases.

[7]  Wilfrid Boireau,et al.  Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth , 2012, Nature Medicine.

[8]  H. Saito,et al.  Prevalence and clinical relevance of Th17 cells in patients with gastric cancer. , 2012, The Journal of surgical research.

[9]  C. Datz,et al.  Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth , 2012, Nature.

[10]  K. Pang,et al.  CD8(+) T cells that produce interleukin-17 regulate myeloid-derived suppressor cells and are associated with survival time of patients with gastric cancer. , 2012, Gastroenterology.

[11]  K. Mills,et al.  IL‐17‐producing γδ T cells and innate lymphoid cells , 2012, European journal of immunology.

[12]  G. Montrucchio,et al.  Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome. , 2012, Experimental and therapeutic medicine.

[13]  Xuexian O Yang,et al.  A Protective Role by Interleukin-17F in Colon Tumorigenesis , 2012, PloS one.

[14]  C. Elmets,et al.  IL-17 Mediated Inflammation Promotes Tumor Growth and Progression in the Skin , 2012, PloS one.

[15]  D. Han,et al.  Role of IL-17A in the development of colitis-associated cancer. , 2011, Carcinogenesis.

[16]  Huaxi Xu,et al.  Increased IL-17-producing CD4(+) T cells in patients with esophageal cancer. , 2012, Cellular immunology.

[17]  T. Mcclanahan,et al.  IL-10 elicits IFNγ-dependent tumor immune surveillance. , 2011, Cancer cell.

[18]  A. Bothwell,et al.  IL-17F deficiency inhibits small intestinal tumorigenesis in ApcMin/+ mice. , 2011, Biochemical and biophysical research communications.

[19]  K. Mills,et al.  Caspase-1-processed IL-1 family cytokines play a vital role in driving innate IL-17. , 2011, Cytokine.

[20]  H. Alshaker,et al.  IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors , 2011, Cancer Cell International.

[21]  Kathleen R. Cho,et al.  Mutant KRAS promotes hyperplasia and alters differentiation in the colon epithelium but does not expand the presumptive stem cell pool. , 2011, Gastroenterology.

[22]  Y. Mao,et al.  The profile of Th17 subset in glioma. , 2011, International immunopharmacology.

[23]  Yoichiro Iwakura,et al.  Review Functional Specialization of Interleukin-17 Family Members , 2022 .

[24]  J. Galon,et al.  Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. , 2011, Cancer research.

[25]  W. Zou,et al.  TH17 cells in tumour immunity and immunotherapy , 2011, Nature Reviews Immunology.

[26]  Hua Yu,et al.  IL-17 enhances tumor development in carcinogen-induced skin cancer. , 2010, Cancer research.

[27]  C. Dong,et al.  IL-17 family member cytokines: regulation and function in innate immunity. , 2010, Cytokine & growth factor reviews.

[28]  C. Tato,et al.  Innate IL-17-producing cells: the sentinels of the immune system , 2010, Nature Reviews Immunology.

[29]  W. Zou,et al.  TH17 cells in tumour immunity and immunotherapy , 2010, Nature Reviews Immunology.

[30]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[31]  D. Zelterman,et al.  Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis , 2010, Proceedings of the National Academy of Sciences.

[32]  Cynthia L Sears,et al.  A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses , 2009, Nature Medicine.

[33]  C. Dong,et al.  The IL-17/IL-23 axis of inflammation in cancer: friend or foe? , 2009, Current opinion in investigational drugs.

[34]  H. Clevers,et al.  Single Lgr5 stem cells build crypt–villus structures in vitro without a mesenchymal niche , 2009, Nature.

[35]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[36]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[37]  Ozge Canli,et al.  gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. , 2009, Cancer cell.

[38]  R. Broaddus,et al.  Regulation of inflammatory responses by IL-17F , 2008, The Journal of experimental medicine.

[39]  M. Karin,et al.  Autocrine IL-6 signaling: a key event in tumorigenesis? , 2008, Cancer cell.

[40]  Kathleen R. Cho,et al.  Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. , 2007, Cancer research.

[41]  Stefan Wirtz,et al.  TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling , 2004 .

[42]  R. Kiesslich,et al.  TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. , 2004, Immunity.

[43]  Daniel Metzger,et al.  Tissue‐specific and inducible Cre‐mediated recombination in the gut epithelium , 2004, Genesis.

[44]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[45]  Takuji Tanaka,et al.  A novel inflammation‐related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate , 2003, Cancer science.

[46]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[47]  J. Shellito,et al.  Requirement of Interleukin 17 Receptor Signaling for Lung Cxc Chemokine and Granulocyte Colony-Stimulating Factor Expression, Neutrophil Recruitment, and Host Defense , 2001, The Journal of experimental medicine.

[48]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[49]  Reynaldo Sequerra,et al.  High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP , 2000, Nature Genetics.

[50]  R. Zinkernagel,et al.  Impaired immune and acute-phase responses in interleukin-6-deficient mice , 1994, Nature.

[51]  G. Freeman,et al.  Cloning of Ly-5 cDNA. , 1985, Proceedings of the National Academy of Sciences of the United States of America.